DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 2019</td>
<td>Update of data in Chapters 2, 3, and 7</td>
</tr>
<tr>
<td>October 2014</td>
<td>Addendum to the toxicological profile</td>
</tr>
<tr>
<td>October 1990</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P.  
David W. Wohlers, Ph.D.  
Lisa Ingerman, Ph.D., DABT

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA  
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.
# CONTENTS

DISCLAIMER ........................................................................................................ ii
FOREWORD ........................................................................................................... iii
VERSION HISTORY .......................................................................................... v
CONTRIBUTORS & REVIEWERS ....................................................................... vi
CONTENTS ......................................................................................................... vii
LIST OF FIGURES ............................................................................................... ix
LIST OF TABLES ................................................................................................. x

## CHAPTER 1. RELEVANCE TO PUBLIC HEALTH
1.1 OVERVIEW AND U.S. EXPOSURES ............................................................... 1
1.2 SUMMARY OF HEALTH EFFECTS ............................................................. 1
1.3 MINIMAL RISK LEVELS (MRLs) ................................................................. 3

## CHAPTER 2. HEALTH EFFECTS
2.1 INTRODUCTION .......................................................................................... 4
2.2 DEATH ......................................................................................................... 22
2.3 BODY WEIGHT ........................................................................................... 23
2.4 RESPIRATORY ............................................................................................ 23
2.5 CARDIOVASCULAR .................................................................................... 24
2.6 GASTROINTESTINAL ............................................................................... 24
2.7 HEMATOLOGICAL ...................................................................................... 25
2.8 MUSCULOSKELETAL ............................................................................... 26
2.9 HEPATIC .................................................................................................... 26
2.10 RENAL ....................................................................................................... 27
2.11 DERMAL ................................................................................................... 27
2.12 OCULAR .................................................................................................... 27
2.13 ENDOCRINE ............................................................................................. 27
2.14 IMMUNOLOGICAL ................................................................................... 27
2.15 NEUROLOGICAL ...................................................................................... 28
2.16 REPRODUCTIVE ....................................................................................... 28
2.17 DEVELOPMENTAL .................................................................................. 29
2.18 OTHER NONCANCER ........................................................................... 29
2.19 CANCER .................................................................................................... 29
2.20 GENOTOXICITY ....................................................................................... 32
2.21 THOROTRAST .......................................................................................... 33

## CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS
3.1 TOXICOKINETICS .................................................................................... 42
3.1.1 Absorption ............................................................................................ 42
3.1.2 Distribution ........................................................................................... 44
3.1.3 Metabolism ........................................................................................... 49
3.1.4 Excretion ............................................................................................... 49
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 52
3.1.6 Animal-to-Human Extrapolations .......................................................... 64
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ......................................................... 64
3.3 BIOMARKERS OF EXPOSURE AND EFFECT ........................................... 65
3.3.1 Biomarkers of Exposure ........................................................................ 66
3.3.2 Biomarkers of Effect ............................................................................. 67
LIST OF FIGURES

2-1. Overview of the Number of Studies Examining Thorium Health Effects........................................ 9
2-2. Levels of Significant Exposure to Thorium – Inhalation ............................................................... 14
2-3. Levels of Significant Exposure to Thorium – Oral........................................................................ 19
3-1. Respiratory Tract Compartments in Which Particles May be Deposited....................................... 55
3-2. Environmental Pathways for Potential Human Health Effects from Thorium............................... 57
3-3. The Human Respiratory Tract Model: Absorption into Blood....................................................... 62
3-4. Structure of the Human Respiratory Tract Model (HATM)............................................................. 63
4-1. Uranium and Thorium Isotope Decay Series Showing the Sources and Decay Products of the
    Two Naturally Occurring Isotopes of Thorium.................................................................................. 73
5-1. Number of NPL Sites with Thorium and Thorium Compounds Contamination............................. 76
6-1. Summary of Existing Health Effects Studies on Thorium By Route and Endpoint......................... 106
# LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Thorium ................................................................. 3

2-1. Levels of Significant Exposure to Thorium – Inhalation ........................................... 10

2-2. Levels of Significant Exposure to Thorium – Oral ...................................................... 17

2-3. Levels of Significant Exposure to Thorium – Dermal ................................................. 21

2-4. Standardized Mortality Ratios for All Cancers and Lung Cancers Among Male Thorium Workers ................................................................. 30

2-5. Selected Thorotrast Treatment-Related Health Effects in Humans ......................... 36

3-1. The Median Concentrations of Thorium Isotopes in Autopsy Samples from Grand Junction, Colorado, and Washington, DC (in pCi/kg Wet Weight) ................................................................. 45

3-2. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity ......................................................................................... 56

3-3. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract .................................................. 58

4-1. Chemical Identity of Thorium and Compounds ......................................................... 69

4-2. Physical and Chemical Properties of Thorium and Compounds .............................. 71

4-3. Percent Occurrence and the Energies of the Major Alpha Particles Emitted by Thorium Isotopes with Atomic Masses Ranging from 223 to 234 ................................................................. 74

5-1. Facilities that Produce, Process, or Use Thorium Dioxide ....................................... 79

5-2. United States Companies with Thorium Processing and Fabricating Capacity .......... 80

5-3. Releases to the Environment from Facilities that Produce, Process, or Use Thorium Dioxide ................................................................. 85

5-4. Lowest Limit of Detection Based on Standards ......................................................... 92

5-5. Summary of Environmental Levels of Thorium ....................................................... 93

5-6. $^{232}$Th Content in Fresh Fruits, Vegetables, and Tea ............................................... 97

5-7. Thorium Levels in Bones of Colorado and Pennsylvania Residents ......................... 98

5-8. Thorium Isotopic Concentration in Three Occupational Cases and the General Population of Grand Junction, Colorado (pCi/kg) ................................................................. 99

7-1. Regulations and Guidelines Applicable to Thorium .................................................. 113